

Introduction <i>F. Zannad</i>	A1
Potassium homoeostasis and pathophysiology of hyperkalaemia <i>K. P. Kjeldsen and T. A. Schmidt</i>	A2
Hyperkalaemia: aetiology, epidemiology, and clinical significance <i>J. Tromp and P. van der Meer</i>	A6
Current treatment and unmet needs of hyperkalaemia in the emergency department <i>Z. Rafique, T. Chouihed, A. Mebazaa and W. Frank Peacock</i>	A12
Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia <i>S. Vijayakumar, J. Butler and G. L. Bakris</i>	A20
Pharmacology of new treatments for hyperkalaemia: patiomer and sodium zirconium cyclosilicate <i>G. M. C. Rosano, I. Spoletini and S. Agewall</i>	A28
New frontiers for management of hyperkalaemia: the emergence of novel agents <i>M. E. Nassif and M. Kosiborod</i>	A34
New treatments for hyperkalaemia: clinical use in cardiology <i>S. Vijayakumar, J. Butler and S. D. Anker</i>	A41
A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology <i>P. Rossignol</i>	A48
Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments <i>F. Zannad, J. P. Ferreira and B. Pitt</i>	A55